Get the Stockscreener App
6.59
5.59%
-0.39
After Hours:
6.61
0.02
+0.30%
Recursion Pharmaceuticals Inc stock is traded at $6.59, with a volume of 5.28M.
It is down -5.59% in the last 24 hours and down -9.48% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.98
Open:
$6.89
24h Volume:
5.28M
Relative Volume:
0.93
Market Cap:
$1.97B
Revenue:
$43.88M
Net Income/Loss:
$-328.07M
P/E Ratio:
-4.7754
EPS:
-1.38
Net Cash Flow:
$-300.33M
1W Performance:
-1.20%
1M Performance:
-9.48%
6M Performance:
-33.90%
1Y Performance:
-13.86%
1-Day Range:
$6.59
$7.095
1-Week Range:
$6.59
$7.30
52-Week Range:
$4.97
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals executive sells $42,004 in stock, buys $6,360 worth - Investing.com
769,230 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by Perceptive Advisors LLC - MarketBeat
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk - The Motley Fool
Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $9.40 - MarketBeat
Scientech Research LLC Invests $1.05 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders - PR Newswire
Recursion Pharmaceuticals Inc(RXRX) Price Target Increased by 7.12% to 17.17 - MSN
Benjamin F. Edwards & Company Inc. Has $1.27 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - MSN
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Experts predict Recursion Pharmaceuticals Inc’s (RXRX) current quarter earnings growth rate - US Post News
Recursion Thinks AI Can Lower The High Failure Rate Of New Pharmaceutical Drugs - Forbes
How to Take Advantage of moves in (RXRX) - Stock Traders Daily
Recursion Pharmaceuticals director sells over $78k in company stock By Investing.com - Investing.com Australia
Is Recursion Pharmaceuticals Stock a Buy? - Yahoo Finance
Recursion Pharmaceuticals Inc [RXRX] Shares Fall Approximately -17.77% Over the Year - Knox Daily
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Recursion Pharmaceuticals director sells over $78k in company stock By Investing.com - Investing.com South Africa
Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals director sells over $78k in company stock - Investing.com India
Recursion Pharmaceuticals director sells over $78k in company stock - Investing.com
Recursion Pharmaceuticals director sells over $78k in company stock By Investing.com - Investing.com UK
Angle celebrates agreement with Recursion Pharmaceuticals - Marketscreener.com
ANGLE signs pilot study agreement with AI-powered Recursion Pharmaceuticals - Proactive Investors USA
ANGLE plc Clinches Deal with Recursion Pharmaceuticals - TipRanks
ANGLE signs pilot study agreement with AI-powered Recursion Pharmaceuticals - Proactive Investors UK
Angle PLC Announces Agreement with Recursion Pharmaceuticals - AccessWire
Angle PLC Announces Agreement with Recursion Pharmaceuticals - StockTitan
Angle signs new agreement US biotech Recursion - Vox Markets
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% Higher - MarketBeat
Market Insights: Recursion Pharmaceuticals Inc (RXRX)’s Notable Gain of 1.65, Closing at 6.76 - The Dwinnex
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Lingotto Investment Management LLP - MarketBeat
Arizona State Retirement System Has $358,000 Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
The Significance of Moving Averages in Recursion Pharmaceuticals Inc Inc. (RXRX) Price Performance - The InvestChronicle
Principal Financial Group Inc. Sells 362,215 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals CFO Secora Michael sells shares worth $187,228 - Investing.com
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock - Insider Monkey
Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down to $6.32 - MarketBeat
Recursion: AI Is Only As Good As The Data (NASDAQ:RXRX) - Seeking Alpha
Bank of New York Mellon Corp Acquires 178,994 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
(RXRX) Proactive Strategies - Stock Traders Daily
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers - Insider Monkey
10 Worst ARK Stocks To Buy According To Short Sellers - Insider Monkey
Recursion Pharmaceuticals CEO sells shares worth over $240,000 By Investing.com - Investing.com Australia
Recursion Pharmaceuticals CEO sells shares worth over $240,000 - Investing.com
Recursion Pharmaceuticals CEO sells shares worth over $240,000 - Investing.com India
Recursion Pharmaceuticals CEO sells shares worth over $240,000 By Investing.com - Investing.com Canada
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $120,800.00 in Stock - MarketBeat
Recursion Pharmaceuticals CEO sells shares worth over $240,000 By Investing.com - Investing.com UK
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):